Vladimir Savransky

Associate Director | Toxicology

Vladimir Savransky, MD/PhD has many years of pharmacological and toxicological experience in the development of biologic products, small molecules and device combination products. Prior to joining ToXcel, Vladimir served as a preclinical/nonclinical development lead at Emergent BioSolutions Inc. where he designed and executed nonclinical development plans, authored nonclinical sections of regulatory submissions, and managed preclinical development programs for various products. During his carrier, he has designed and overseen numerous nonclinical development programs for a variety of products, including vaccines, monoclonal and polyclonal antibodies, live biotherapeutics and protein therapeutics as well as small molecules and drug/device combination products. Dr. Savransky routinely performs nonclinical safety assessments, and both authors and reviews development plans for a diverse array of drugs and biologic products. He has written numerous nonclinical sections of pre-INDs, INDs, BLA/NDAs and eCTDs on behalf of clients, and regularly assists and contributes with FDA meetings and other interactions with regulatory agencies. Dr. Savransky works closely with sponsors to source and manage nonclinical and GLP safety studies at contract research organizations (CROs) and performs GLP compliance inspections on behalf of clients.

Vladimir received his MD and PhD in biomedical sciences from Pavlov First Saint Petersburg State Medical University (Russia) in 1994. He subsequently completed post-doctoral training at Johns Hopkins University School of Medicine. Dr. Savransky joined toXcel LLC as an Associate Director of Toxicology in 2024.

Featured Publications

• Cornelissen AS, van den Berg RM, Langenberg JP, van Grol M, Bross R, Pittman J, Cochrane L, Savransky V. Effective skin decontamination with RSDL® (reactive skin decontamination lotion kit) following dermal exposure to a Novichok class nerve agent. Chem Biol Interact. 2024 Apr 18;395:111001.
• van den Berg RM, Joosen MJA, Savransky V, Cochrane L, Noort D. Inactivation of ricin by constituents present in a skin decontamination lotion. Chem Biol Interact. 2022 Sep 25;365:110055.
• Rao VV, Godin CS, Lacy MJ, Inglefield JR, Park S, Blauth B, Reece JJ, Ionin B, Savransky V. Evaluation of the AV7909 Anthrax Vaccine Toxicity in Sprague Dawley Rats Following Three Intramuscular Administrations. Int J Toxicol. 2021 Oct;40(5):442-452.
• Kentrop J, Savransky V, Klaassen SD, van Groningen T, Bohnert S, Cornelissen AS, Cochrane L, Barry J, Joosen MJA. Pharmacokinetics and efficacy of atropine sulfate/obidoxime chloride co-formulation against VX in a guinea pig model. Regul Toxicol Pharmacol. 2021 Feb;119:104823.
• Shearer JD, Henning L, Sanford DC, Li N, Skiadopoulos MH, Reece JJ, Ionin B, Savransky V. Efficacy of the AV7909 anthrax vaccine candidate in guinea pigs and nonhuman primates following two immunizations two weeks apart. Vaccine. 2021 Jan 3;39(1):1-5.